DECIPHERA PHARMACEUTICALS IN's ticker is DCPH and the CUSIP is 24344T101. A total of 148 filers reported holding DECIPHERA PHARMACEUTICALS IN in Q1 2023. The put-call ratio across all filers is 0.80 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2024 | $29 | -66.7% | 1,817 | -66.2% | 0.00% | -100.0% |
Q4 2023 | $87 | +17.6% | 5,372 | -8.0% | 0.00% | 0.0% |
Q3 2023 | $74 | -9.8% | 5,841 | 0.0% | 0.00% | 0.0% |
Q2 2023 | $82 | -5.7% | 5,841 | +4.3% | 0.00% | 0.0% |
Q1 2023 | $87 | -15.5% | 5,600 | -11.3% | 0.00% | 0.0% |
Q4 2022 | $103 | -99.9% | 6,313 | +2.5% | 0.00% | 0.0% |
Q3 2022 | $114,000 | +40.7% | 6,161 | +0.5% | 0.00% | 0.0% |
Q2 2022 | $81,000 | +42.1% | 6,130 | -1.1% | 0.00% | – |
Q1 2022 | $57,000 | -75.2% | 6,196 | -8.5% | 0.00% | -100.0% |
Q3 2021 | $230,000 | -12.2% | 6,769 | -5.6% | 0.00% | 0.0% |
Q2 2021 | $262,000 | +6.5% | 7,170 | +30.9% | 0.00% | -77.8% |
Q1 2021 | $246,000 | -27.6% | 5,479 | -8.0% | 0.01% | -30.8% |
Q4 2020 | $340,000 | +13.7% | 5,956 | +2.4% | 0.01% | 0.0% |
Q3 2020 | $299,000 | -16.2% | 5,819 | -2.8% | 0.01% | -23.5% |
Q2 2020 | $357,000 | +55.9% | 5,986 | +62.4% | 0.02% | +325.0% |
Q4 2019 | $229,000 | – | 3,687 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
New Leaf Venture Partners, L.L.C. | 1,209,571 | $19,824,869 | 14.35% |
Redmile Group, LLC | 3,593,317 | $58,894,466 | 2.41% |
BRAIDWELL LP | 3,271,513 | $53,620,098 | 1.80% |
Parkman Healthcare Partners LLC | 344,920 | $5,653,239 | 1.50% |
ARMISTICE CAPITAL, LLC | 5,172,000 | $84,769,080 | 1.48% |
Ikarian Capital, LLC | 367,119 | $6,017,081 | 1.45% |
Sunesis Advisors, LLC | 96,299 | $1,578,341 | 1.01% |
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 2,349,228 | $38,503,847 | 0.80% |
Hillsdale Investment Management Inc. | 328,200 | $5,379,198 | 0.46% |
Avidity Partners Management LP | 1,126,000 | $18,455,140 | 0.40% |